Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 8/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093039 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL30302924 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL30093103 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL30339793 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL30093123 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL30302936 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL29800070 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL29799990 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL30798752 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 | |
| SCHEMBL30305362 | 1.00 | IL23R (0.51) | IL23RKISS1RACECTSCMAGI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2025-06-19 | — | — | US | claimed |
| US-20240252586-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2024-08-01 | — | — | US | claimed |
| CN-118265536-A | Engineered antibacterial peptides and uses thereof | 肽逻辑公司 | 2024-06-28 | — | — | CN | claimed |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | claimed |
| US-20220249599-A1 | TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2022-08-11 | — | — | US | claimed |
| US-20250320266-A1 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20240252586-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20220249599-A1 | TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | IL23R 610/4885KISS1R 3745/4885ACE 1426/4885 |
| US-20220249599-A1 | TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | NGLY1, ANPEP, VIP | IL23R 1023/4885KISS1R 1422/4885ACE 1927/4885 |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | IAPP, VIP, NGLY1 | IL23R 1571/4885KISS1R 3225/4885ACE 1227/4885 |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | IL23R 610/4885KISS1R 3745/4885ACE 1426/4885 |
| US-20250277002-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | IL23R 2492/4885KISS1R 3536/4885ACE 2135/4885 |
| US-20230107222-A1 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | NGLY1, PRF1, LNPEP | IL23R 2492/4885KISS1R 3536/4885ACE 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.